Download PDF
Semin Thromb Hemost 1998; 24(5): 449-451
DOI: 10.1055/s-2007-996038
Copyright © 1998 by Thieme Medical Publishers, Inc.

Platelet Hemostatic Capacity (PHC) and Fibrinolytic Inhibitors during Pregnancy

Shigenori Suzuki, Setuko Morishita
  • College of Medical Technology, Hokkaido University, Sapporo, Japan
Further Information

Publication History

Publication Date:
06 February 2008 (online)

  PDF Download  Permissions and Reprints

Abstract

Platelet hemostatic capacity (PHC) was measured in blood from pregnant patients during all three trimesters using the PFA-100™ system. Closure times were shorter with both cartridge systems during pregnancy, compared to non-pregnant controls, suggesting increased PHC. Thrombin/antithrombin (TAT) complex and prothrombin fragment 1 + 2 (F1+2) levels were elevated during pregnancy and increased over time. Also, plasma levels of plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2) increased during pregnancy. The data suggest increased coagulability during pregnancy. It is suggested that estrogen may play a role in this state of hypercoagulability. Seven days after delivery all of the measured parameters, except TAT levels, were again within normal range.

Keywords:

PFA-100™ - primary hemostasis - pregnancy - TAT - F 1+2 - PAI-1 - PAI-2 - estrogen